Assessment Status |
Awaiting response from Applicant |
|
HTA ID |
22058 |
|
Drug |
Tucatinib |
|
Brand |
Tukysa® |
|
Indication |
In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. |
|
Rapid review commissioned |
23/08/2022 |
|
Rapid review completed |
20/09/2022 |
|
Full pharmacoeconomic assessment commissioned by HSE |
28/09/2022 |
|
Pre-submission consultation with Applicant |
12/12/2023 |
|
Full submission received from Applicant |
14/03/2024 |
|
Assessment process on hold as updated submission required |
06/12/2024 |
|
Updated submission received |
10/03/2025 |
|
Preliminary Review sent to Applicant |
10/04/2025 |
|